Clinical Trial

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-03-30 -> 2026-09-30 2026-05-29
minor Completion pushed: 2026-03-30 -> 2026-09-30 2026-05-29
Trial Details
NCT Number NCT05882734
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Non-Small Cell Lung Cancer
Enrollment 61 participants
Start Date 2023-09-13
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-28